Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 11.3 10.8 104.4% View Chart
P/BV x 1.5 1.6 92.4% View Chart
Dividend Yield % 0.7 0.6 115.5%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
GLENMARK PHARMA
Mar-21
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,023573 178.6%   
Low Rs333195 170.7%   
Sales per share (Unadj.) Rs422.8387.8 109.0%  
Earnings per share (Unadj.) Rs92.034.4 267.5%  
Cash flow per share (Unadj.) Rs110.050.1 219.5%  
Dividends per share (Unadj.) Rs4.002.50 160.0%  
Avg Dividend yield %0.60.7 90.6%  
Book value per share (Unadj.) Rs374.3249.6 149.9%  
Shares outstanding (eoy) m585.94282.17 207.7%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.61.0 162.0%   
Avg P/E ratio x7.411.2 66.0%  
P/CF ratio (eoy) x6.27.7 80.5%  
Price / Book Value ratio x1.81.5 117.8%  
Dividend payout %4.37.3 59.8%   
Avg Mkt Cap Rs m397,398108,353 366.8%   
No. of employees `000NANA-   
Total wages/salary Rs m35,35023,437 150.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m247,746109,439 226.4%  
Other income Rs m3,809502 758.4%   
Total revenues Rs m251,555109,941 228.8%   
Gross profit Rs m81,48021,289 382.7%  
Depreciation Rs m10,5544,436 237.9%   
Interest Rs m7453,531 21.1%   
Profit before tax Rs m73,99013,825 535.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,0984,124 487.4%   
Profit after tax Rs m53,8929,701 555.5%  
Gross profit margin %32.919.5 169.1%  
Effective tax rate %27.229.8 91.1%   
Net profit margin %21.88.9 245.4%  
BALANCE SHEET DATA
Current assets Rs m198,23573,596 269.4%   
Current liabilities Rs m106,65242,010 253.9%   
Net working cap to sales %37.028.9 128.1%  
Current ratio x1.91.8 106.1%  
Inventory Days Days197 289.4%  
Debtors Days Days5286 60.2%  
Net fixed assets Rs m135,77867,093 202.4%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m218,71370,148 311.8%   
Net worth Rs m219,29970,430 311.4%   
Long term debt Rs m1,68438,888 4.3%   
Total assets Rs m334,013140,689 237.4%  
Interest coverage x100.34.9 2,041.2%   
Debt to equity ratio x00.6 1.4%  
Sales to assets ratio x0.70.8 95.4%   
Return on assets %16.49.4 173.9%  
Return on equity %24.613.8 178.4%  
Return on capital %33.815.9 213.0%  
Exports to sales %53.80-   
Imports to sales %16.40-   
Exports (fob) Rs m133,248NA-   
Imports (cif) Rs m40,615NA-   
Fx inflow Rs m133,24835,753 372.7%   
Fx outflow Rs m44,94612,023 373.8%   
Net fx Rs m88,30223,729 372.1%   
CASH FLOW
From Operations Rs m33,28911,312 294.3%  
From Investments Rs m5,987-6,752 -88.7%  
From Financial Activity Rs m-13,648-4,418 308.9%  
Net Cashflow Rs m25,831278 9,285.0%  

Share Holding

Indian Promoters % 48.8 46.7 104.5%  
Foreign collaborators % 3.1 0.0 -  
Indian inst/Mut Fund % 38.3 35.1 109.2%  
FIIs % 20.8 24.1 86.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 53.4 90.3%  
Shareholders   338,639 310,516 109.1%  
Pledged promoter(s) holding % 14.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex, Nifty End Marginally Lower; Metal Stocks Witness Selling(Closing)

After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 23, 2022 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - MERCURY LAB. COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS